2006D-0383 | Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases | |||||||||||||||||||||||
FDA Comment Number : | EC2692 | |||||||||||||||||||||||
Submitter : | Mrs. Kristine Witt | Date & Time: | 12/06/2006 09:12:22 | |||||||||||||||||||||
Organization : | Mrs. Kristine Witt | |||||||||||||||||||||||
Category : | Individual Consumer | |||||||||||||||||||||||
Issue Areas/Comments | ||||||||||||||||||||||||
GENERAL | ||||||||||||||||||||||||
GENERAL | ||||||||||||||||||||||||
I would ask that the FDA favor all viable alternatives to fetal tissue for vaccine manufacturing and not approve any protocols for vaccine production that rely on fetal tissue use.
| ||||||||||||||||||||||||